Incidence and clinical outcome of renal amyloidosis : a retrospective study
Joint Authors
Source
Saudi Journal of Kidney Diseases and Transplantation
Issue
Vol. 24, Issue 5 (30 Sep. 2013), pp.950-958, 9 p.
Publisher
Saudi Center for Organ Transplantation
Publication Date
2013-09-30
Country of Publication
Saudi Arabia
No. of Pages
9
Main Subjects
Topics
Abstract EN
The kidneys are affected in almost all patients with amyloid A in secondary amyloidosis (AA) amyloidosis but less frequently in immunoglobulin light chains in primary systemic amyloidosis (AL) amyloidosis.
In this study, we present the incidence, etiology, clinical manifestations, biochemical features and clinical course of renal amyloidosis.
We conducted a retrospective study on a group of 40 cases with renal biopsy-proven amyloidosis.
They constituted 2.5% of the total cases of renal biopsies performed in the Theodor Bilharz Research Institute, Cairo, Egypt, during the period from February 2003 to May 2009.
The mean age (30 males, ten females) was 36.51 ± 10.32 years.
Thirty-two of the cases had secondary AA amyloidosis and eight cases had primary AL amyloidosis.
The causes of secondary amyloidosis were as follows: 12 (30%) familial Mediterranean fever (FMF), eight (20%) pulmonary tuberculosis, four (10%) chronic osteomyelitis, four (10%) bronchiectasis, three (7%) rheumatoid arthritis and one (2%) rheumatic heart disease.
The eight cases of primary AL amyloidosis comprised of five cases that were associated with myloma (13%) and three (8%) cases that were idiopathic.
Among the 23 patients with AA amyloidosis, after six months of treatment with colchicine, the proteinuria improved, serum albumin level increased and edema disappeared in 13 patients.
In four cases of AA amyloidosis who were clinically and biochemically normal after cholchicine therapy, a second renal biopsy disclosed decreased amyloid deposition compared with the first biopsy.
In the three renal transplanted patients who had amyloidosis secondary to FMF and were treated with colchicines, AA amyloidosis did not recur in the transplanted kidney.
It might be possible that in AL amyloidosis, treatment with methotrexate, melphalan and prednisolone may improve survival.
The incidence of renal amyloidosis is increasing and colchicine can be used in secondary amyloidosis as it may have an effect on reducing the production of the amyloid precursor proteins and in reducing proteinuria.
American Psychological Association (APA)
Abd Allah, Imad& Imam, Wakid. 2013. Incidence and clinical outcome of renal amyloidosis : a retrospective study. Saudi Journal of Kidney Diseases and Transplantation،Vol. 24, no. 5, pp.950-958.
https://search.emarefa.net/detail/BIM-355812
Modern Language Association (MLA)
Abd Allah, Imad& Imam, Wakid. Incidence and clinical outcome of renal amyloidosis : a retrospective study. Saudi Journal of Kidney Diseases and Transplantation Vol. 24, no. 5 (2013), pp.950-958.
https://search.emarefa.net/detail/BIM-355812
American Medical Association (AMA)
Abd Allah, Imad& Imam, Wakid. Incidence and clinical outcome of renal amyloidosis : a retrospective study. Saudi Journal of Kidney Diseases and Transplantation. 2013. Vol. 24, no. 5, pp.950-958.
https://search.emarefa.net/detail/BIM-355812
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references : p. 957-958
Record ID
BIM-355812